OLMA Olema Pharmaceuticals, Inc. Stock Quote

OLMA [NASD]

Index	-	P/E	-	EPS (ttm)	-0.39	Insider Own	14.40%	Shs Outstand	38.13M	Perf Week	1.26%
Market Cap	1.63B	Forward P/E	-	EPS next Y	-1.26	Insider Trans	40.58%	Shs Float	32.92M	Perf Month	-3.11%
Income	-14.90M	PEG	-	EPS next Q	-0.18	Inst Own	17.20%	Short Float	2.16%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-96.40%	Inst Trans	-	Short Ratio	3.74	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-22.30%	ROA	-	Target Price	60.67	Perf Year	-
Cash/sh	3.35	P/C	12.72	EPS next 5Y	-	ROE	-	52W Range	35.73 - 60.27	Perf YTD	-11.34%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-29.27%	Beta	-
Dividend %	-	Quick Ratio	24.50	Sales past 5Y	-	Gross Margin	-	52W Low	19.31%	ATR	2.76
Employees	21	Current Ratio	24.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.14	Volatility	5.11% 6.42%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.36	Prev Close	41.86
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	190.16K	Price	42.63
Recom	1.50	SMA20	-4.46%	SMA50	-6.50%	SMA200	-6.50%	Volume	68,573	Change	1.84%

Dec-14-20

Initiated

JP Morgan

Overweight

$52

Dec-14-20

Initiated

Jefferies

Buy

$70

Dec-14-20

Initiated

Cowen

Outperform

Dec-14-20

Initiated

Canaccord Genuity

Buy

$60

Dec-31-20 03:42PM	Biotech IPO Frenzy Brings in 3 Stocks to Buy TipRanks
Dec-17-20 07:00AM	Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference GlobeNewswire +8.03%
Dec-07-20 07:39AM	Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 GlobeNewswire -8.31%
Dec-03-20 05:18PM	Kinnate Biopharma Stock Nearly Doubles in Debut. More Deals Are Coming. Barrons.com
Nov-23-20 04:01PM	Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +7.93%
Nov-20-20 01:33PM	Maravai LifeSciences Jumps Nearly 19% in IPO, While Sotera Pops 17% Barrons.com
Nov-19-20 06:39PM	IPOs Are Back After Election Pause. Olema Pharmaceuticals Stock Jumped 158%. Barrons.com

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	Nov 23	Buy	19.00	425,000	8,075,000	3,270,544	Nov 23 04:59 PM
Graham G. Walmsley	Director	Nov 23	Buy	19.00	1,160,000	22,040,000	1,160,000	Nov 23 04:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience